All In Biotech

Drug Trial Radar · NCT05835752

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RAY1225

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

68

Actual

Start

May 18, 2023

Primary completion

Mar 1, 2024

Study completion Mar 23, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225

Conditions

  • Obese
  • Healthy

Interventions

  • RAY1225Drug

    Administered SC

  • PlaceboDrug

    Administered SC

  • RAY1225Drug

    Administered SC

  • PlaceboDrug

    Administered SC

  • RAY1225Drug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)Time frame: Baseline through Day 29 (Part A)
  2. Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)Time frame: Baseline through Day 64 (QW,Part B&C);baseline through Day 71 (Q2W,Part B&C)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanfang Hospital,South Medical Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.